Trial Profile
Role of food intolerance and effect of protease inhibitor in patients with irritable bowel syndrome (IBS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2013
Price :
$35
*
At a glance
- Drugs Camostat mesilate (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- 30 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 10 Feb 2010 New trial record